Global Blood Plasma Market Size By Type (Immunoglobulin, Albumin), By Application (Hospitals and Clinics, Research Laboratories), By Region, And Segment Forecasts, 2023 to 2032

The Global Blood Plasma Market was valued at USD 28.4 billion in 2023 and is projected to surpass USD 52.7 billion by 2031, expanding at a CAGR of 8.2% during the forecast period from 2023 to 2031. This growth is fueled by the rising demand for plasma-derived therapies, increasing prevalence of immunodeficiency and neurological disorders, and expanded applications of plasma in biopharmaceutical R&D. The market is also supported by technological advancements in plasma fractionation and enhanced awareness of plasma donation programs worldwide.

Drivers:

1. Growing Demand for Plasma-Derived Therapies:

With rising cases of rare and chronic diseases such as primary immunodeficiencies, hemophilia, and autoimmune disorders, the demand for plasma-derived therapies like immunoglobulins, albumin, and clotting factors is accelerating globally.

2. Technological Advancements in Fractionation:

Improved fractionation techniques and processing efficiency are increasing the yield and purity of plasma proteins, supporting a robust supply of high-quality plasma products.

3. Government and NGO Initiatives Promoting Plasma Donation:

Public awareness campaigns and national plasma collection programs are bolstering plasma supply, especially in developed countries like the U.S. and parts of Europe.

Restraints:

1. High Operational Costs:

Plasma collection, storage, and fractionation are capital-intensive processes. Establishing new plasma centers requires significant regulatory approvals and infrastructure investments.

2. Risk of Product Contamination and Regulatory Scrutiny:

The complex manufacturing process involves biological materials, making it susceptible to contamination. This mandates stringent quality and safety controls, increasing compliance costs.

Opportunity:

1. Rising Demand in Emerging Economies:

As healthcare infrastructure improves across Asia-Pacific, Latin America, and parts of the Middle East, the demand for plasma-based treatments is witnessing a sharp uptick.

2. Expansion of Plasma Applications in Research and Personalized Medicine:

Blood plasma’s increasing use in regenerative medicine, oncology, and diagnostics presents significant untapped potential for growth.

Market by System Type Insights:

Based on system type, the Immunoglobulin segment held the largest market share in 2023. It continues to dominate due to its wide-ranging applications in treating primary immune deficiencies and neurological conditions like CIDP and multifocal motor neuropathy. Meanwhile, the Albumin segment is anticipated to grow rapidly due to its use in liver diseases, burns, and surgeries.

Market by End-Use Insights:

Hospitals emerged as the largest end-use segment in 2023, accounting for more than 45% of the total market share. The rising rate of chronic disease hospitalization and surgical procedures is contributing to this dominance. Pharmaceutical companies are also significant end-users due to growing R&D initiatives to develop next-generation plasma therapies.

Market by Regional Insights:

North America dominated the global blood plasma market in 2023, owing to a strong network of plasma collection centers, favorable reimbursement policies, and the presence of leading pharmaceutical firms. However, the Asia-Pacific region is projected to witness the fastest growth rate during the forecast period due to increasing healthcare investments and rising awareness regarding plasma donation.

Competitive Scenario:

Major players in the Global Blood Plasma Market include Grifols S.A., CSL Behring, Takeda Pharmaceutical Company, Octapharma AG, Kedrion Biopharma, Bio Products Laboratory Ltd, LFB Group, and China Biologic Products Holdings Inc. These companies are focused on geographic expansion, strategic acquisitions, and technological innovations.

Key Market Developments:

In 2023, Grifols opened a state-of-the-art plasma fractionation plant in the U.S. to boost global supply.

CSL Behring partnered with global NGOs in 2024 to expand plasma collection networks in underserved regions.

Takeda launched an AI-integrated plasma screening solution in 2025 to improve safety and efficiency in donor selection.

Scope of Work – Global Blood Plasma Market

FAQs:

1) What is the current market size of the Global Blood Plasma Market?

The market was valued at USD 28.4 billion in 2023.

2) What is the major growth driver of the Global Blood Plasma Market?

The major growth driver is the rising global demand for plasma-derived therapies, especially immunoglobulins and coagulation factors.

3) Which is the largest region during the forecast period in the Global Blood Plasma Market?

North America is the largest region, backed by extensive plasma collection infrastructure and leading market players.

4) Which segment accounted for the largest market share in the Global Blood Plasma Market?

The Immunoglobulin segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Blood Plasma Market?

Key players include Grifols S.A., CSL Behring, Takeda, Octapharma, Kedrion Biopharma, and China Biologic Products.

Let me know if you'd like this converted into a downloadable DOCX or PDF format.